Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nanjing Leads Biolabs Co's enterprise value is €1,338.22 Mil.
Nanjing Leads Biolabs Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-20.23 Mil. Therefore, Nanjing Leads Biolabs Co's EV-to-EBITDA for today is -66.16.
The historical rank and industry rank for Nanjing Leads Biolabs Co's EV-to-EBITDA or its related term are showing as below:
FRA:0DX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.02 Med: -43.14 Max: -24.72
Current: -66.91
During the past 3 years, the highest EV-to-EBITDA of Nanjing Leads Biolabs Co was -24.72. The lowest was -79.02. And the median was -43.14.
FRA:0DX's EV-to-EBITDA is ranked worse than 100% of 407
companies
in the Biotechnology industry
Industry Median: 13.94
vs FRA:0DX: -66.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nanjing Leads Biolabs Co (FRA:0DX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nanjing Leads Biolabs Co's PE Ratio (TTM) for today is calculated as:
Nanjing Leads Biolabs Co's share price for today is €7.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanjing Leads Biolabs Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co EV-to-EBITDA Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
-45.66
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-EBITDA
0.00
0.00
0.00
0.00
-45.66
FRA:0DX vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's EV-to-EBITDA falls into.
Nanjing Leads Biolabs Co's current Enterprise Value is €1,338.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanjing Leads Biolabs Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-20.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co (FRA:0DX) has a EV-to-EBITDA of -66.16 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanjing Leads Biolabs Co. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 407 companies in the Biotechnology industry.
Is Nanjing Leads Biolabs Co's EV-to-EBITDA too high?
Nanjing Leads Biolabs Co's current EV-to-EBITDA is -66.16. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #999999 out of 407 companies for EV-to-EBITDA. This places Nanjing Leads Biolabs Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.94, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nanjing Leads Biolabs Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Leads Biolabs Co's current EV-to-EBITDA is -66.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current EV-to-EBITDA of -66.16. The current EV-to-EBITDA is -66.16. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current EV-to-EBITDA is -66.16 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
